Steadybase.

Tevogen Inc.

Website LinkedIn Latest 10-K
  • TVGN ยท Nasdaq
  • Biological Products, (No Diagnostic Substances)
  • Warren, NJ
  • CIK 0001860871

Updated from SEC filings through

Top things to know

Executives

Tevogen Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Warren, NJ. It trades as TVGN on Nasdaq.

Five-year financials

MetricFY2025FY2024FY2023FY2022
Revenue Not on file Not on file Not on file Not on file
Operating income -$26.1M
10-K, 2026-03-31
-$53.6M
10-K, 2026-03-31
-$8.8M
10-K, 2025-04-02
Not on file
SG&A $15.0M
10-K, 2026-03-31
$22.5M
10-K, 2026-03-31
$4.4M
10-K, 2025-04-02
$953K
10-K, 2024-04-29
Net income -$26.3M
10-K, 2026-03-31
-$13.7M
10-K, 2026-03-31
-$60.5M
10-K, 2025-04-02
$4.4M
10-K, 2024-04-29

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Ryan H. Saadi Ryan H. Saadi Chief Executive Officer Form 4, September 16, 2026
Kirti Desai Kirti Desai Chief Financial Officer 8-K, September 16, 2026
Neal Flomenberg Named in proxy
bio: Chief Scientific Officer and Global R&D Lead
DEF 14A, August 3, 2026
Jeffrey Feike Jeffrey Feike Board member (per proxy)
bio: Director
DEF 14A, August 3, 2026
Victor Sordillo Victor Sordillo Board member (per proxy)
bio: Director
DEF 14A, August 3, 2026
Susan Podlogar Board member (per proxy)
bio: Director
DEF 14A, August 3, 2026

What Tevogen Inc. does

Tevogen is a healthcare company focused on addressing unmet needs across biotechnology, technology, and healthcare services.

Company website description, 10-K for the year ending November 7, 2026

Shares and governance

Shares outstanding 68.7 million (as of November 16, 2026) 10-Q, November 16, 2026
Public float $63.7M (as of June 30, 2025) 10-K/A, April 30, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 16, 2026
Latest proxy statement Meeting August 3, 2026 (filed August 3, 2026) DEF 14A, August 3, 2026
Auditor Kpmg LLP (Philadelphia, Pennsylvania) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
March 13, 2026 Neal Flomenberg
See Remarks
Sale 972 $7K Form 4, March 17, 2026

Recent 8-K events

  • 8-K filed 2026-11-04
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-11-03
    • Item 1.01 Entry into a material definitive agreement
    • Item 2.03 Creation of a direct financial obligation
    • Item 3.02 Unregistered sales of equity securities
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-09-30
    • Item 8.01 Other events
  • 8-K filed 2026-09-16
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-09-10
    • Item 8.01 Other events
  • 8-K filed 2026-08-26
    • Item 5.02 Departure or appointment of directors or officers; compensation
    • Item 5.03 Amendments to articles or bylaws; change in fiscal year
    • Item 5.07 Submission of matters to a vote of security holders
  • 8-K filed 2026-07-30
    • Item 5.03 Amendments to articles or bylaws; change in fiscal year
  • 8-K filed 2026-04-22
    • Item 3.01 Notice of delisting or failure to meet listing standards
  • 8-K filed 2026-03-25
    • Item 8.01 Other events
  • 8-K filed 2026-03-04
    • Item 3.03 Material modification to rights of security holders
    • Item 5.03 Amendments to articles or bylaws; change in fiscal year
    • Item 7.01 Regulation FD disclosure

Frequently asked questions about Tevogen Inc.

What does Tevogen Inc. do?
In its own words, from Item 1 of its 10-K: "Tevogen is a healthcare company focused on addressing unmet needs across biotechnology, technology, and healthcare services."
Who is the CFO of Tevogen Inc.?
Kirti Desai, Chief Financial Officer, as named in a 8-K filed September 16, 2026.
Where is Tevogen Inc. headquartered?
Warren, NJ.
What is Tevogen Inc.'s stock ticker?
TVGN, TVGNW on Nasdaq.
What industry is Tevogen Inc. in?
Biological Products, (No Diagnostic Substances), SIC code 2836.
What is Tevogen Inc.'s website?
tevogen.com.
When does Tevogen Inc. report earnings next?
February 12, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Tevogen Inc. a public company?
Yes. Tevogen Inc. files with the SEC under CIK 0001860871 and trades as TVGN.
Who audits Tevogen Inc.?
Kpmg LLP, Philadelphia, Pennsylvania, as named in its latest annual report (10-K).
How many shares of Tevogen Inc. are outstanding?
68.7 million shares as of November 16, 2026, from its 10-Q filed November 16, 2026.
What is Tevogen Inc.'s public float?
$63.7M as of June 30, 2025, as reported on the cover of its 10-K/A filed April 30, 2026.
How many business segments does Tevogen Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 16, 2026.
When is Tevogen Inc.'s annual shareholder meeting?
August 3, 2026, per its proxy statement (DEF 14A) filed August 3, 2026.
Have Tevogen Inc. insiders traded stock recently?
Since March 13, 2026, officers and directors reported 1 open-market sale worth about $7K and 0 purchases on Forms 4 and 5. The most recent: Neal Flomenberg (See Remarks) sold 972 shares on March 13, 2026.